Search

Your search keyword '"Paquette, R"' showing total 248 results
Start Over Author "Paquette, R"
248 results on '"Paquette, R"'

1. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia

Author

Muschen, Markus, Sun, H, Lin, DC, Guo, X, Masouleh, BK, Gery, S, Cao, Q, Alkan, S, Ikezoe, T, Akiba, C, and Paquette, R

Abstract

Survival of cancer cells relies on the unfolded protein response (UPR) to resist stress triggered by the accumulation of misfolded proteins within the endoplasmic reticulum (ER). The IRE1α-XBP1 pathway, a key branch of the UPR, is activated in many cancers

Published
2016

3. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Author

Cortes, JE, Kim, D-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, DiPersio, J, DeAngelo, DJ, Abruzzese, E, Rea, D, Baccarani, M, Müller, MC, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, VM, Clackson, T, Turner, CD, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, T, Goldman, JM, Shah, NP, and Kantarjian, H

Subjects
Hematology, Clinical Research, Cancer, Rare Diseases, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Imidazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Pyridazines, Thrombocytopenia, Thrombosis, Young Adult, PACE Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundPonatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).MethodsWe enrolled 449 heavily pretreated patients who had CML or Ph-positive ALL with resistance to or unacceptable side effects from dasatinib or nilotinib or who had the BCR-ABL T315I mutation. Ponatinib was administered at an initial dose of 45 mg once daily. The median follow-up was 15 months.ResultsAmong 267 patients with chronic-phase CML, 56% had a major cytogenetic response (51% of patients with resistance to or unacceptable side effects from dasatinib or nilotinib and 70% of patients with the T315I mutation), 46% had a complete cytogenetic response (40% and 66% in the two subgroups, respectively), and 34% had a major molecular response (27% and 56% in the two subgroups, respectively). Responses were observed regardless of the baseline BCR-ABL kinase domain mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%. No single BCR-ABL mutation conferring resistance to ponatinib was detected. Among 83 patients with accelerated-phase CML, 55% had a major hematologic response and 39% had a major cytogenetic response. Among 62 patients with blast-phase CML, 31% had a major hematologic response and 23% had a major cytogenetic response. Among 32 patients with Ph-positive ALL, 41% had a major hematologic response and 47% had a major cytogenetic response. Common adverse events were thrombocytopenia (in 37% of patients), rash (in 34%), dry skin (in 32%), and abdominal pain (in 22%). Serious arterial thrombotic events were observed in 9% of patients; these events were considered to be treatment-related in 3%. A total of 12% of patients discontinued treatment because of an adverse event.ConclusionsPonatinib had significant antileukemic activity across categories of disease stage and mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440 .).

Published
2013

5. SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment

Author

Figueiredo, J.C., primary, Ihenacho, U., additional, Merin, N.M., additional, Hamid, O., additional, Darrah, J., additional, Gong, J., additional, Paquette, R., additional, Mita, A.C., additional, Vescio, R., additional, Mehmi, I., additional, Basho, R., additional, Salvy, S.J., additional, Shirazipour, C.H., additional, Caceres, N., additional, Finster, L.J., additional, Coleman, B., additional, Arnow, H.U., additional, Florindez, L., additional, Sobhani, K., additional, Prostko, J.C., additional, Frias, E.C., additional, Stewart, J.L., additional, Merchant, A., additional, and Reckamp, K.L., additional

Published
2022
Full Text
View/download PDF

6. Ponatinib in Refractory Ph-Positive Leukemias: A Phase 2 Trial

Author

Cortes, J E, Kim, D-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F E, Apperley, J, Khoury, H J, Talpaz, M, DiPersio, J, DeAngelo, D J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V M, Clackson, T, Turner, C D, Haluska, F G, Guilhot, F, Deininger, M W, Hochhaus, A, Hughes, T, Goldman, J, Shah, N P, and Kantarjian, H

Published
2013

7. 1611P Health-related quality of life, vaccine uptake and immune response among cancer patients undergoing treatment during the COVID-19 pandemic

Author

Figueiredo, J.C., primary, Merin, N., additional, Ihenacho, U., additional, Hamid, O., additional, Hendifar, A.E., additional, Vescio, R., additional, Paquette, R., additional, Natale, R.B., additional, Darrah, J., additional, Basho, R., additional, McArthur, H., additional, Nguyen, N., additional, Punwani, N., additional, Herrera, E., additional, Cheng, S., additional, Salvy, S-J., additional, Datta, G., additional, Figlin, R., additional, Merchant, A., additional, and Reckamp, K.L., additional

Published
2021
Full Text
View/download PDF

16. LONG-TERM EFFICACY AND SAFETY OF PONATINIB IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE PIVOTAL PHASE 2 PACE TRIAL

Author

Cortes, JE, Pinilla-Ibarz, J, Le Coutre, PD, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, Baccarani, M, Lustgarten, S, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, TP, Shah, NP, Kantarjian, HM, and National Institute for Health Research

Subjects
Science & Technology, Immunology, Hematology, Life Sciences & Biomedicine, 1102 Cardiovascular Medicine And Haematology
Published
2016

17. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Author

Cortes, Je1, Kim, Dw, Pinilla Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, Fe, Apperley, Jf, Khoury, Hj, Talpaz, M, Dipersio, J, Deangelo, Dj, Abruzzese, E, Rea, D, Baccarani, M, Müller, Mc, Gambacorti Passerini, C, Wong, S, Lustgarten, S, Rivera, Vm, Clackson, T, Turner, Cd, Haluska, Fg, Guilhot, F, Deininger, Mw, Hochhaus, A, Hughes, T, Goldman, Jm, Shah, Np, Kantarjian, H, Pace, Investigators, Saglio, Giuseppe, Cortes, J, Kim, D, Pinilla Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F, Apperley, J, Khoury, H, Talpaz, M, Dipersio, J, Deangelo, D, Abruzzese, E, Rea, D, Baccarani, M, Müller, M, GAMBACORTI PASSERINI, C, Wong, S, Lustgarten, S, Rivera, V, Clackson, T, Turner, C, Haluska, F, Guilhot, F, Deininger, M, Hochhaus, A, Hughes, T, Goldman, J, Shah, N, and Kantarjian, H

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Protein Kinase Inhibitor, Philadelphia chromosome, Gastroenterology, chemistry.chemical_compound, Young Adult, hemic and lymphatic diseases, Internal medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Imidazole, Aged, Aged, 80 and over, business.industry, Ponatinib, General Medicine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Middle Aged, medicine.disease, Rash, Thrombocytopenia, Hematologic Response, Dasatinib, Leukemia, Nilotinib, chemistry, Immunology, Thrombosi, Female, medicine.symptom, business, Pyridazine, Bosutinib, medicine.drug, Human
Abstract

Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonineto-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome– positive acute lymphoblastic leukemia (Ph-positive ALL). Methods We enrolled 449 heavily pretreated patients who had CML or Ph-positive ALL with resistance to or unacceptable side effects from dasatinib or nilotinib or who had the BCR-ABL T315I mutation. Ponatinib was administered at an initial dose of 45 mg once daily. The median follow-up was 15 months. Results Among 267 patients with chronic-phase CML, 56% had a major cytogenetic response (51% of patients with resistance to or unacceptable side effects from dasatinib or nilotinib and 70% of patients with the T315I mutation), 46% had a complete cytogenetic response (40% and 66% in the two subgroups, respectively), and 34% had a major molecular response (27% and 56% in the two subgroups, respectively). Responses were observed regardless of the baseline BCR-ABL kinase domain mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%. No single BCR-ABL mutation conferring resistance to ponatinib was detected. Among 83 patients with accelerated-phase CML, 55% had a major hematologic response and 39% had a major cytogenetic response. Among 62 patients with blast-phase CML, 31% had a major hematologic response and 23% had a major cytogenetic response. Among 32 patients with Ph-positive ALL, 41% had a major hematologic response and 47% had a major cytogenetic response. Common adverse events were thrombocytopenia (in 37% of patients), rash (in 34%), dry skin (in 32%), and abdominal pain (in 22%). Serious arterial thrombotic events were observed in 9% of patients; these events were considered to be treatment-related in 3%. A total of 12% of patients discontinued treatment because of an adverse event.

Published
2013

20. Imatinib Discontinuation and Tki Switching Patterns in the Retrospective and Prospective Cohorts in Simplicity, A Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (PTS) in Routine Clinical Practice

Author

Zyczynski, T, primary, Khoury, J, additional, Goldberg, S, additional, Mauro, M, additional, Michallet, M, additional, Paquette, R, additional, Foreman, A, additional, Subar, M, additional, Turner, M, additional, Manley Daumont, M, additional, Hehlmann, R, additional, and Simonsson, B, additional

Published
2016
Full Text
View/download PDF

21. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Author

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson Ansah A, Legros L, Harousseau JL, Rigal Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde Dahl T, Hjorth Hansen H, Jedrzejczak W, Dmoszynska A, Starzak Dwozdz J, Holowiecki J, Kyrcz Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent D.J., PANE, FABRIZIO, Saglio, G, Kim, Dw, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, Re, Hochhaus, A, Hughes, Tp, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, Ra, Kantarjian, Hm, Moiraghi, B, Perez, M, Greil, R, Valent, P, Bosly, A, Martiat, P, Noens, L, André, M, Verhoef, G, Conchon, M, Souza, C, Nonino, A, Hungria, V, Zanichelli, Ma, Colturato, V, Forrest, D, Lipton, Jh, Savoie, Ml, Delage, R, Lalancette, M, Quintero, G, Gomez, M, Klamova, H, Faber, E, Bjerrum, Ow, Fredriksen, H, Vestergaard, H, Marcher, C, Kamel, H, Elzawam, H, Porkka, K, Remes, K, Reiffers, J, Guilhot, F, Facon, T, Tulliez, M, Guerci Bresler, Ap, Nicolini, Fe, Charbonnier, A, Rea, D, Johnson Ansah, A, Legros, L, Harousseau, Jl, Rigal Huguet, F, Escoffre, M, Gardembas, M, Guyotat, D, Cahn, Jy, Gattermann, N, Ottmann, O, Niederwieser, D, Stegelmann, F, Schafhausen, P, Brümmendorf, T, Duyster, J, Blumenstengel, K, Scheid, C, Kneba, M, Kwong, Yl, Masszi, T, Petrini, M, Alimena, G, Di Raimondo, F, Rosti, G, Rotoli, B, Pane, Fabrizio, Pungolino, E, Amadori, S, Abruzzese, E, Fioritoni, G, Lauria, F, Bosi, A, Martelli, M, Rambaldi, A, Ferrara, F, Nobile, F, Gobbi, M, Carella, Am, Orlandi, Em, Leoni, P, Tiribelli, M, Levis, A, Imamura, M, Takahashi, N, Tsukamoto, N, Chiba, S, Nagai, T, Okamoto, S, Miura, O, Kurokawa, M, Ohnishi, K, Toba, K, Nakao, S, Tomita, A, Miyamura, K, Hino, M, Maeda, Y, Kimura, A, Kawaguchi, T, Miyazaki, Y, Nakaseko, C, Jinnai, I, Matsuda, A, Matsumura, I, Ishikawa, J, Ohyashiki, K, Okada, M, Usuki, K, Kobayashi, Y, Ohishi, K, Imai, K, Miyawaki, S, Kanda, Y, Park, Sy, Kim, Hj, Sohn, Sk, Lee, Kh, Jung, Cw, Ong, Tc, Gómez Almaguer, D, Kassack, J, Ossenkoppele, Gj, Gedde Dahl, T, Hjorth Hansen, H, Jedrzejczak, W, Dmoszynska, A, Starzak Dwozdz, J, Holowiecki, J, Kyrcz Krzemieñ, S, Kuliczkowski, K, Zaritsky, A, Turkina, A, Pospelova, T, Goh, Yt, Koh, Lp, Demitrovicova, L, Mistrik, M, Ruff, P, Louw, V, Dreosti, Lm, Novitzky, N, Cohen, G, Cervantes, F, Cañizo, C, de Paz, R, del Castillo, S, Perez Encinas, M, Sanz Alonso, M, Marin, F, Pérez López, R, Hernandez Boluda, J, Echeveste Gutierrez, Ma, Odriozola, J, Herrera, P, Steegman, Jl, Conde, E, Lopez, P, Giraldo, P, Boque, C, Heredia, B, Font, Aj, Rodriguez, Rf, Rodriguez, Mj, Batlle, J, Stenke, L, Lehmann, S, Wadenvik, H, Simonsson, B, Markevärn, B, Själander, A, Richter, J, Bjoreman, M, Eriksson, Km, Chalandon, Y, Shih, Ly, Yao, M, Wang, Mc, Jootar, S, Bunworasate, U, Ulkü, B, Haznedar, R, Undar, B, Sahin, B, Marin, D, Smith, G, Byrne, J, Holyoake, T, Kalaycio, M, Akard, L, Heaney, M, Al Janadi, A, Goldberg, S, Powell, B, Harker, Wg, Shea, T, Gingrich, R, Glass, J, Paquette, R, Siegrist, C, Woodson, M, Fehrenbacher, L, Koh, H, Flinn, I, Arrowsmith, E, Ervin, T, Guerra, M, Wallach, H, Berry, W, Burke, J, Edenfield, W, Guzley, G, Davis, J, Richards, D, Schlossman, D, Kolibaba, K, Alemany, C, Savin, M, Robbins, G, Lopez, J, Goldman, Jm, Camm, J, Schiffer, Ca, and Sargent, D. J.

Published
2010

24. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Author

Komrokji, R. S., primary, Mailloux, A. W., additional, Chen, D.-T., additional, Sekeres, M. A., additional, Paquette, R., additional, Fulp, W. J., additional, Sugimori, C., additional, Paleveda-Pena, J., additional, Maciejewski, J. P., additional, List, A. F., additional, and Epling-Burnette, P. K., additional

Published
2014
Full Text
View/download PDF

26. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Author

Verstovsek, S., primary, Mesa, R. A., additional, Gotlib, J., additional, Levy, R. S., additional, Gupta, V., additional, DiPersio, J. F., additional, Catalano, J. V., additional, Deininger, M. W. N., additional, Miller, C. B., additional, Silver, R. T., additional, Talpaz, M., additional, Winton, E. F., additional, Harvey, J. H., additional, Arcasoy, M. O., additional, Hexner, E. O., additional, Lyons, R. M., additional, Paquette, R., additional, Raza, A., additional, Vaddi, K., additional, Erickson-Viitanen, S., additional, Sun, W., additional, Sandor, V., additional, and Kantarjian, H. M., additional

Published
2013
Full Text
View/download PDF

27. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Author

Mesa, R. A., primary, Kiladjian, J.-J., additional, Verstovsek, S., additional, Al-Ali, H. K., additional, Gotlib, J., additional, Gisslinger, H., additional, Levy, R., additional, Siulnik, A., additional, Gupta, V., additional, Khan, M., additional, DiPersio, J. F., additional, McQuitty, M., additional, Catalano, J. V., additional, Hunter, D. S., additional, Knoops, L., additional, Deininger, M., additional, Cervantes, F., additional, Miller, C., additional, Vannucchi, A. M., additional, Silver, R. T., additional, Barbui, T., additional, Talpaz, M., additional, Barosi, G., additional, Winton, E. F., additional, Mendeson, E., additional, Harvey, J. H., additional, Arcasoy, M. O., additional, Hexner, E., additional, Lyons, R. M., additional, Paquette, R., additional, Raza, A., additional, Sun, W., additional, Sandor, V., additional, Kantarjian, H. M., additional, and Harrison, C., additional

Published
2013
Full Text
View/download PDF

29. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency

Author

Yang, L, primary, Mailloux, A, additional, Rollison, D E, additional, Painter, J S, additional, Maciejewski, J, additional, Paquette, R L, additional, Loughran, T P, additional, McGraw, K, additional, Makishima, H, additional, Radhakrishnan, R, additional, Wei, S, additional, Ren, X, additional, Komrokji, R, additional, List, A F, additional, and Epling-Burnette, P K, additional

Published
2012
Full Text
View/download PDF

31. Stratigraphy of the crater Copernicus

Author

Paquette, R

Subjects
Lunar And Planetary Exploration
Abstract

The stratigraphy of copernicus based on its olivine absorption bands is presented. Earth based spectral data are used to develop models that also employ cratering mechanics to devise theories for Copernican geomorphology. General geologic information, spectral information, upper and lower stratigraphic units and a chart for model comparison are included in the stratigraphic analysis.

Published
1984

37. Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM)

Author

Cripe, L., primary, McGuire, W., additional, Wertheim, M., additional, Eisenberg, P., additional, Stadler, W., additional, Paquette, R., additional, Logan, T., additional, Zimmerman, T., additional, Matei, D., additional, and Matulonis, U., additional

Published
2007
Full Text
View/download PDF

43. Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Author

Sawyers, Charles L., primary, Kantarjian, H., primary, Shah, N., primary, Cortes, J., primary, Paquette, R., primary, Donato, N., primary, Nicoll, J., primary, Bleickardt, E., primary, Chen, T.-T., primary, and Talpaz, M., primary

Published
2005
Full Text
View/download PDF

46. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)

Author

Shah, N., primary, Sawyers, C. L., additional, Kantarjian, H. M. M., additional, Donato, N., additional, Nicoll, J., additional, Cortes, J., additional, Paquette, R., additional, Huang, F., additional, Clark, E., additional, and Talpaz, M., additional

Published
2005
Full Text
View/download PDF

48. Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Author

Giles, Francis, primary, Schiffer, C., primary, Kantarjian, H., primary, Fischer, T., primary, Paquette, R., primary, Pelov, D. M., primary, Resta, D. J., primary, Cohen, P. S., primary, Wang, Y. F., primary, and Stone, R., primary

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results